Connect with us

Hi, what are you looking for?

Thursday, Oct 6, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Canada

Optimi Health partners with patient advocate to launch new psilocybin product

The company and Hartle will host a virtual press conference scheduled for Wednesday at 1 pm

Thomas Hartle was among the first Canadians to get authorization to have access to medical psilocybin. Photo via Optimi Health

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) is partnering up with psilocybin patient advocate Thomas Hartle and his charity to release a psilocybin product made for patients.

On Tuesday, the Canadian psychedelics company announced the partnership with Hartle in commemoration of the two-year anniversary of Hartle being one of Canada’s first applicants to be approved to use psilocybin for medical purposes. The company will donate proceeds of sales directly to Hartle’s charity for facilitating patient access to psilocybin-assisted therapy.

The company and Hartle will host a virtual press conference scheduled for Wednesday at 1 pm where the details of the partnership and the new product will be discussed.

“Honestly, until I started receiving my psilocybin-assisted therapy treatments two years ago, I wasn’t sure if I could handle the daily stress of knowing that I was dying,” said Hartle.

“Having a therapeutic psilocybin product made in my honour, which I had never considered as a possibility, gives me pause to reflect on how many have lost their battles before ever experiencing the amazing benefits of psilocybin therapy.”

“I am excited to be partnering with Optimi to provide that opportunity to the people who need it most, with the hope that they will receive the same life-restoring gift that I have experienced.”

Read more: Optimi enters natural psilocybin supply agreement with Filament Health

Read more: Optimi Health enters psilocybin mushroom supply agreement with Halucenex Life Sciences

“Honouring Thomas’s incredible optimism and appreciation for life with his own natural, Canadian-grown psilocybin product is something we will cherish as a company forever,” said Bill Ciprick, CEO of Optimi Health.

“We share Thomas’s energy and passion for creating the perfect psilocybin experience, and we look forward to providing a vital service to Special Access Program patients while further demonstrating to regulators that psychedelic-assisted therapies can be integrated into our existing healthcare framework.”

 

natalia@mugglehead.com

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Psychedelics

The company plans to use mushroom tea to treat patients pending regulatory approvals

Canada

These relatively new stores remind people about the final days of the cannabis prohibition era in Canada

Medical and Pharmaceutical

New study also suggests that plant-derived medicines can reduce inflammation and improve mental health

Psychedelics

Shipment marks company's first successful export to Europe and second to date